ArticleDer Nervenarzt2019
[Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].
Article in Der Nervenarzt, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Schizophrenia and catatonia: from ICD-10 to ICD-11.Der Nervenarzt · 2025Article
- [Schizophrenia and catatonia: from ICD-10 to ICD-11. German version].Der Nervenarzt · 2025Review
- Blood and CSF anti-neuronal antibodies testing in psychotic syndromes: a retrospective analysis from a tertiary psychiatric hospital.Immunologic research · 2024Article
- [Hashimoto's encephalopathy-An underdiagnosed disease in psychiatry?]Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2022Article
- Cerebrospinal fluid findings in patients with psychotic symptoms-a retrospective analysis.Scientific reports · 2021Article
- Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations.European archives of psychiatry and clinical neuroscience · 2020Review
- Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations.European archives of psychiatry and clinical neuroscience · 2020Review
- Diagnosing Organic Causes of Schizophrenia Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in Psychosis (FDPP).Diagnostics (Basel, Switzerland) · 2020Article
- Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis.Translational psychiatry · 2020Article
- Psychiatric Manifestation of Anti-LGI1 Encephalitis.Brain sciences · 2020Article
- Cerebrospinal Fluid Findings of 36 Adult Patients with Autism Spectrum Disorder.Brain sciences · 2020Article
- Probable Autoimmune Depression in a Patient With Multiple Sclerosis and Antineuronal Antibodies.Frontiers in psychiatry · 2020Article
- Anti-N-Methyl-D-Aspartate-Receptor Encephalitis: A 10-Year Follow-Up.Frontiers in psychiatry · 2020Article
- Novel Antineuronal Autoantibodies With Somatodendritic Staining Pattern in a Patient With Autoimmune Psychosis.Frontiers in psychiatry · 2020Article
- The Challenge of Assessing Mild Neuroinflammation in Severe Mental Disorders.Frontiers in psychiatry · 2020Review
- [Autoantibody-associated schizophreniform psychoses: clinical symptomatology].Der Nervenarzt · 2019Article
- Psychiatric Presentation of Anti-NMDA Receptor Encephalitis.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of secondary, possibly organic schizophreniform psychoses, autoantibody(AB)-associated autoimmune encephalitis (AE) plays an increasingly important role. If this is suspected, clinical investigations, including laboratory, magnetic resonance imaging, electroencephalography and cerebrospinal fluid (CSF) analyses are recommended. The AB screening should include the most frequent ABs against neuronal cell surface antigens (NMDA receptor [R], CASPR2, LGI1, AMPA-R, GABAB-R), intracellular antigens (Hu, Ri, Yo, CV2/CRMP5, Ma2[Ta], amphiphysin, GAD65), thyroid tissue (TG, TPO, TRAK), and antinuclear antigens (ANAs). The ABs against cell surface antigens and GAD65 should be examined directly in serum and CSF. Less frequent ABs can be looked for in a second step. Furthermore, immunofluorescence tests on brain slices of rodents may identify previously unknown ABs. The detection of ABs in combination with further findings can lead to the diagnosis of AE which implies new therapeutic opportunities with immunomodulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.